• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

    11/4/24 8:00:00 AM ET
    $AZTA
    $BV
    $LVWR
    Industrial Machinery/Components
    Technology
    Real Estate
    Real Estate
    Get the next $AZTA alert in real time by email

    William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board

    Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus

    Reaffirms Full-Year 2024 Financial Guidance

    BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board.

    William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing initiative to ensure a best-in-class Board that has resulted in significant Board refreshment in the past two years.

    Also, as part of the Board's process, Quentin Koffey, Founder, Managing Partner and Chief Investment Officer of Politan Capital Management ("Politan"), which owns 9.4% of Azenta common stock, joins as a Director. Azenta and Politan have entered into a cooperation agreement that provides for the addition of Mr. Koffey to the Board, among other matters.

    "The addition of these new independent directors further demonstrates Azenta's commitment to ensuring we have a well-rounded Board with the right mix of skillsets and experience. We are excited to welcome William, Quentin and Alan," said Frank E. Casal, Chairman of Azenta's Board of Directors. "Their diverse set of skills complement our Board's existing strengths. William's operational expertise leading companies to profitable growth, Quentin's experience enhancing capital allocation, and Alan's track record of fostering life sciences innovation will be invaluable as we continue our focus on expanding margins and enhancing profitability to further drive long-term shareholder value creation."

    "I am honored to join Azenta's Board," said Mr. Cornog. "Since becoming a standalone business, Azenta has built a strong foundation with a clear runway for growth, and the Company is poised to generate meaningful shareholder value."

    "As long-term investors in Azenta, we are confident the Company has significant opportunities ahead to unlock and drive shareholder value," said Mr. Koffey. "We appreciate our constructive engagement with Azenta, and I look forward to collaborating with the Board and management to best position the Company for the future."

    "In the dynamic life sciences industry, Azenta has proven its commitment to innovate for customers," said Mr. Malus. "I am thrilled to join the Board and help advance Azenta's mission to enable impactful scientific breakthroughs faster."

    Azenta's Board has established a new Value Creation Committee to, in consultation with senior management of the Company, assist and advise the Board in its responsibilities relating to long-term value creation, including growth and cost initiatives and high-level capital deployment. The initial members of the Value Creation Committee are William Cornog, Quentin Koffey, Martin Madaus, Alan Malus, and John Marotta and the committee will be chaired by William Cornog.

    Azenta also reaffirms its full year 2024 financial guidance provided on August 6th, 2024.

    As part of the cooperation agreement and to facilitate collaboration, Azenta and Politan have agreed to customary standstill, voting and other provisions. The cooperation agreement will be filed on a Form 8-K with the U.S. Securities and Exchange Commission.

    About William L. Cornog

    William L. Cornog is the former head of KKR Capstone, the portfolio operations team of KKR & Co. In addition to leading Capstone, Mr. Cornog chaired KKR's portfolio management committees for the Americas, Europe, Asia, Infrastructure, Impact & Technology Growth and was a member of the Investment & Distribution and Valuation Committees. Currently, Mr. Cornog is a board member at Brightview Holdings Inc. (NYSE:BV) and LiveWire (NYSE:LVWR). He is Chairman of the Audit Committee and the Conflicts Committee of LiveWire.

    About Quentin Koffey

    Quentin Koffey is Founder, Managing Partner and Chief Investment Officer of Politan Capital Management. Prior to founding Politan in 2021, Mr. Koffey was a partner at Senator Investment Group LP from 2019 to 2021, a Portfolio Manager for Strategic Investments at The D.E. Shaw Group from 2017 to 2019 and a Portfolio Manager at Elliott Management Corporation from 2010 to 2017.

    About Alan J. Malus

    Alan J. Malus is the former Corporate Executive Vice President of Thermo Fisher. Prior to that, Mr. Malus served as President, Laboratory Products and Services at Thermo Fisher. He has held various leadership positions and senior executive positions in finance, marketing, commercial development and operations since joining Thermo Fisher in 1998. Previously, Mr. Malus served as an independent director at PHC Holdings Corp., a global healthcare company, headquartered in Japan.

    About Azenta Life Sciences

    Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

    Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

    "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934

    Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results and the forward-looking statements in this release to differ materially from our expectations. These statements are based on the facts known to management at the time they are made. Forward-looking statements in this release include but are not limited to statements about: the three new independent directors appointed to the Board; the expected impact each new independent director may have on Azenta, including with respect to future shareholder value; Azenta's future plans and expectations with respect to the Board; and the role and impact of the newly created Value Creation Committee of the Board. Factors that could cause results to differ from our expectations include the following: our ability to reduce costs effectively; the volatility of the life sciences markets Azenta serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that future results will not be materially different from the forward-looking statements in this release. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

    AZENTA INVESTOR CONTACTS:

    Yvonne Perron

    Vice President, Financial Planning & Analysis and Investor Relations

    [email protected]

    Sherry Dinsmore

    [email protected] 

    AZENTA MEDIA CONTACT:

    Emily Claffey

    FGS Global

    [email protected]

    Azenta logo (PRNewsfoto/Azenta)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-announces-the-addition-of-three-new-independent-directors-effective-immediately-and-new-initiative-to-drive-value-302295015.html

    SOURCE Azenta

    Get the next $AZTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTA
    $BV
    $LVWR

    CompanyDatePrice TargetRatingAnalyst
    Azenta Inc.
    $AZTA
    8/6/2025$35.00Mkt Perform → Outperform
    Raymond James
    Azenta Inc.
    $AZTA
    7/22/2025$35.00Equal-Weight
    Stephens
    Azenta Inc.
    $AZTA
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    BrightView Holdings Inc.
    $BV
    12/2/2024$22.00Buy
    BTIG Research
    BrightView Holdings Inc.
    $BV
    11/15/2024Mkt Perform → Outperform
    William Blair
    BrightView Holdings Inc.
    $BV
    8/22/2024$16.00Equal-Weight
    Morgan Stanley
    BrightView Holdings Inc.
    $BV
    8/21/2024$13.00 → $17.00Hold → Buy
    Jefferies
    BrightView Holdings Inc.
    $BV
    7/30/2024$18.00Buy
    Loop Capital
    More analyst ratings

    $AZTA
    $BV
    $LVWR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Azenta upgraded by Raymond James with a new price target

    Raymond James upgraded Azenta from Mkt Perform to Outperform and set a new price target of $35.00

    8/6/25 7:48:53 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Stephens resumed coverage on Azenta with a new price target

    Stephens resumed coverage of Azenta with a rating of Equal-Weight and set a new price target of $35.00

    7/22/25 7:51:21 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta upgraded by Stephens with a new price target

    Stephens upgraded Azenta from Equal-Weight to Overweight and set a new price target of $60.00 from $50.00 previously

    12/18/24 7:25:24 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BV
    $LVWR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and GM, Multiomics Zhou Ginger returned $30,966 worth of Common to the company (1,085 units at $28.54), decreasing direct ownership by 4% to 26,831 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/13/25 4:47:44 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SVP and CHRO Pirogova Olga returned $30,966 worth of Common to the company (1,085 units at $28.54), decreasing direct ownership by 6% to 18,288 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/13/25 4:44:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    New insider Hoover Jennifer claimed ownership of 30,688 shares (SEC Form 3)

    3 - LiveWire Group, Inc. (0001898795) (Issuer)

    8/13/25 10:34:57 AM ET
    $LVWR
    Motor Vehicles
    Consumer Discretionary

    $AZTA
    $BV
    $LVWR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO and Treasurer Lin Lawrence Y. bought $69,900 worth of Common (2,500 units at $27.96), increasing direct ownership by 6% to 46,013 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    8/12/25 4:05:13 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Director Barker Kurtis T bought $530,044 worth of shares (40,000 units at $13.25) (SEC Form 4)

    4 - BrightView Holdings, Inc. (0001734713) (Issuer)

    3/18/25 5:15:04 PM ET
    $BV
    Real Estate

    Director Cornog William L bought $134,950 worth of shares (10,000 units at $13.49) (SEC Form 4)

    4 - BrightView Holdings, Inc. (0001734713) (Issuer)

    2/21/25 4:30:03 PM ET
    $BV
    Real Estate

    $AZTA
    $BV
    $LVWR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrightView Posts Third Quarter Fiscal 2025 Earnings With Record Net Income and Adjusted EBITDA, and Reaffirms Full Year Guidance

    BrightView Holdings, Inc. (NYSE:BV) (the "Company" or "BrightView"), the leading commercial landscaping services company in the United States, today reported unaudited results for the third quarter ended June 30, 2025. THIRD QUARTER FISCAL 2025 SUMMARY Net service revenues decreased 4.1% year-over-year to $708.3 million, Net income increased $8.8 million year-over-year to $32.3 million, Net income margin expansion of 140 basis points, Adjusted EBITDA2 increased 4.9% year-over-year to $113.2 million, Adjusted EBITDA margin2 expansion of 140 basis points, Year-to-date Net cash provided by operating activities of $207.4 million, an increase of $55.3 million, Year-to-date Adjus

    8/6/25 4:10:00 PM ET
    $BV
    Real Estate

    Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance

    BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2025 2025 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 144 $ 143 $ 144 0 % (0) % Organic growth (2) % Sample Management Solutions $ 78 $ 80 $ 81 (3) % (4) % Multiomics $ 66 $ 64 $ 64 4 % 4 % Diluted EPS Continuing Operations

    8/5/25 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology

    BURLINGTON, Mass., July 31, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to enhance the understanding of cardio-kidney-metabolic diseases and drive advancements in precision medicine for patients worldwide. The MyReason research program is an innovative initiative designed to uncover insights into the genetic mechanisms underlying kidney disease. To d

    7/31/25 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BV
    $LVWR
    SEC Filings

    View All

    SEC Form S-3 filed by LiveWire Group Inc.

    S-3 - LiveWire Group, Inc. (0001898795) (Filer)

    8/18/25 5:07:14 PM ET
    $LVWR
    Motor Vehicles
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by BrightView Holdings Inc.

    SCHEDULE 13G/A - BrightView Holdings, Inc. (0001734713) (Subject)

    8/8/25 4:30:10 PM ET
    $BV
    Real Estate

    SEC Form 10-Q filed by Azenta Inc.

    10-Q - Azenta, Inc. (0000933974) (Filer)

    8/6/25 5:19:09 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BV
    $LVWR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BrightView Holdings Inc.

    SC 13G - BrightView Holdings, Inc. (0001734713) (Subject)

    11/14/24 1:28:33 PM ET
    $BV
    Real Estate

    Amendment: SEC Form SC 13G/A filed by BrightView Holdings Inc.

    SC 13G/A - BrightView Holdings, Inc. (0001734713) (Subject)

    11/13/24 7:10:55 PM ET
    $BV
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Azenta Inc.

    SC 13G/A - Azenta, Inc. (0000933974) (Subject)

    11/13/24 4:05:02 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BV
    $LVWR
    Financials

    Live finance-specific insights

    View All

    BrightView Posts Third Quarter Fiscal 2025 Earnings With Record Net Income and Adjusted EBITDA, and Reaffirms Full Year Guidance

    BrightView Holdings, Inc. (NYSE:BV) (the "Company" or "BrightView"), the leading commercial landscaping services company in the United States, today reported unaudited results for the third quarter ended June 30, 2025. THIRD QUARTER FISCAL 2025 SUMMARY Net service revenues decreased 4.1% year-over-year to $708.3 million, Net income increased $8.8 million year-over-year to $32.3 million, Net income margin expansion of 140 basis points, Adjusted EBITDA2 increased 4.9% year-over-year to $113.2 million, Adjusted EBITDA margin2 expansion of 140 basis points, Year-to-date Net cash provided by operating activities of $207.4 million, an increase of $55.3 million, Year-to-date Adjus

    8/6/25 4:10:00 PM ET
    $BV
    Real Estate

    Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance

    BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2025 2025 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 144 $ 143 $ 144 0 % (0) % Organic growth (2) % Sample Management Solutions $ 78 $ 80 $ 81 (3) % (4) % Multiomics $ 66 $ 64 $ 64 4 % 4 % Diluted EPS Continuing Operations

    8/5/25 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Announces Fiscal 2025 Third Quarter Earnings Conference Call and Webcast

    BURLINGTON, Mass., July 23, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 5, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 6, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling imp

    7/23/25 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    $BV
    $LVWR
    Leadership Updates

    Live Leadership Updates

    View All

    Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

    NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

    11/19/24 5:56:00 PM ET
    $AZTA
    $CON
    $ENV
    Industrial Machinery/Components
    Technology
    Medical Specialities
    Health Care

    Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

    William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

    11/4/24 8:00:00 AM ET
    $AZTA
    $BV
    $LVWR
    Industrial Machinery/Components
    Technology
    Real Estate
    Motor Vehicles

    AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

    Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P

    9/4/24 8:00:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology